Share this video  

VJHemOnc is committed to improving our service to you

ASH 2018 | Mohamad Mohty’s myeloma highlights from ASH 2018

Mohamad Mohty
ASH 2018
Multiple Myeloma Antibodies Bortezomib CAR-T Carfilzomib Daratumumab Isatuximab Ixazomib

Mohamad Mohty, MD, PhD, of the University Pierre & Marie Curie, Paris, France, shares his highlights for multiple myeloma (MM) from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. Prof. Mohty discusses advancements offering a promising outlook for MM patients, including BiTEs, CAR T-cell therapies, and daratumumab.

More from Mohamad Mohty

2:16
What to expect from this year's congress
Mohamad Mohty • 28 Feb 2022
1:52
Diving into multiple myeloma and other related diseases
Mohamad Mohty • 28 Feb 2022
2:26
Allo-HSCT and novel drugs for refractory AML
Mohamad Mohty • 25 Sep 2020
3:04
Looking forward to COMy 2022
Mohamad Mohty • 1 Feb 2022

Related Videos

4:28
A.R.R.O.W. study: carfilzomib dosing in frail MM patients
Maria-Victoria Mateos
1:16
Managing CRS in myeloma
Nina Shah
2:26
Managing transplant patients during the COVID-19 pandemic
Christian Chabannon
3:43
DNA methyltransferase inhibitors: daratumumab enhancement for MM
Priya Choudhry
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals